HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PLRX
Pliant Therapeutics, Inc.
There isn't enough reported data to score PLRX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PLRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Strong |
PLRX's balance sheet is currently strong, but its revenue and profitability are weak. There isn't enough data to rate its cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PLRX PE Valuation
PLRX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PLRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect PLRX's revenue to grow, with its earnings and profitability holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PLRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.44 | +$1.44 |
| Q2 2026 | -$1.48 | +$1.92 |
| Q1 2026 | -$1.83 | +$1.78 |
| Q4 2025 | -$2.43 | +$1.04 |
| Q3 2025 | -$2.88 | +$0.45 |
| Q2 2025 | -$3.40 | -$0.32 |
| Q1 2025 | -$3.61 | -$0.75 |
| Q4 2024 | -$3.47 | -$0.72 |
PLRX has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PLRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $248K | -95% |
| Q1 2023 | $1.3M | +6.6% |
| Q4 2022 | $2M | -1.7% |
| Q3 2022 | $1.5M | -8% |
| Q2 2022 | $5M | +179% |
| Q1 2022 | $1.2M | -43% |
| Q4 2021 | $2M | -55% |
| Q3 2021 | $1.6M | -67% |
PLRX's revenue has slid since its 2019 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2023 | -19084% | -18490 points |
| Q1 2023 | -3160% | -902 points |
| Q4 2022 | -1903% | -673 points |
| Q3 2022 | -2156% | -472 points |
| Q2 2022 | -594% | +686 points |
| Q1 2022 | -2259% | -1205 points |
| Q4 2021 | -1231% | -805 points |
| Q3 2021 | -1684% | -1338 points |
PLRX's operating margin was −19084% last quarter, down 18490 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PLRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
PLRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17M | +$4.1M |
| Q2 2026 | -$12.8M | +$27.9M |
| Q1 2026 | -$19.2M | +$29.9M |
| Q4 2025 | -$17.8M | +$30.1M |
| Q3 2025 | -$21.1M | +$12.1M |
| Q2 2025 | -$40.7M | +$5.8M |
| Q1 2025 | -$49.1M | -$17.4M |
| Q4 2024 | -$47.9M | -$22.7M |
PLRX has burned cash in almost every quarter: −$67M over the past year, against −$159M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PLRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PLRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +24.7K shares |
| 1 year | +0.9% | +537K shares |
| 3 years | +3.8% | +2.3M shares |
| 5 years | +73% | +26.2M shares |
| Available history | +184% | +40.1M shares |
PLRX has 62M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | — |
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PLRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2020 | -2.7x | Net Cash |
| Q2 2020 | -7.4x | Net Cash |
| Q1 2020 | -4.5x | Net Cash |
PLRX has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PLRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.9 | Oversold |
| Stochastic | 4.0 | Oversold |
PLRX's weekly RSI is 26 (oversold) and its Stochastic is 4 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PLRX PE vs Healthcare Sector
| Metric | PLRX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PLRX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PLRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.91 | 19% below |
| 20 week MA | $1.04 | 29% below |
| 50 week MA | $1.15 | 36% below |
| 100 week MA | $2.19 | 66% below |
| 200 week MA | $9.83 | 92% below |
PLRX is in a downtrend: it's below all five of its weekly moving averages, and 92% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PLRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.3 | $25.4 | +14% |
| 2021 | $25.4 | $15.4 | -40% |
| 2022 | $15.4 | $18.2 | +19% |
| 2023 | $18.2 | $18.1 | -0.5% |
| 2024 | $18.1 | $13.6 | -25% |
| 2025 | $13.6 | $1.21 | -91% |
| 2026 YTD | $1.21 | $0.74 | -39% |
PLRX has the edge over HIMS on returns for 2026, with the stronger performance.